Development of an innovative Gallium 68 radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT imaging of neuro-endocrine tumors and preliminary clinical evaluation - GALTEP

CHU de Bordeaux0 个研究点开始时间: 2014年1月21日最近更新: 2015年8月4日

试验速览

暂无简介。

•- Patients over 18 years
•- Patient who is suspected of endocrine tumors according to symptomatology, biology or imaging or pathological context (multiple endocrine neoplasia type 1)
•- initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
•- Search of the primary tumor, especially in the case of the inaugural discovery of metastases
•- staging of a known recurrence
•- Search occult recurrence or suspicion of recurrence (clinical, laboratory, imaging doubtful)
•- Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
•- Patient who have signed an informed consent
•- Patient affiliated or beneficiary of regime of social security of a Member State of the European community
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•- Patient with another evolutive cancer disease and/or treated for less than 5 years
•- Pregnant or lactating woman
•- Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)
•- Patient unable to give their free and informed consent
•- Persons placed under judicial protection

发起方

CHU de Bordeaux